{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T13:17:15Z","timestamp":1767964635412,"version":"3.49.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T00:00:00Z","timestamp":1620604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","award":["AAP-2018-REGARDS"],"award-info":[{"award-number":["AAP-2018-REGARDS"]}],"id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s40264-021-01077-9","type":"journal-article","created":{"date-parts":[[2021,5,10]],"date-time":"2021-05-10T09:03:32Z","timestamp":1620637412000},"page":"787-796","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk of Pregnancy Termination and Congenital Anomalies After Domperidone Exposure: A Study in the EFEMERIS Database"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3057-9554","authenticated-orcid":false,"given":"M\u00e9lanie","family":"Araujo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cl\u00e9mentine","family":"Vabre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine","family":"Benevent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agn\u00e8s","family":"Sommet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Damase-Michel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Hurault-Delarue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Lacroix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,10]]},"reference":[{"key":"1077_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/B978-0-444-64150-2.00027-7","volume":"173","author":"E El\u00e9fant","year":"2020","unstructured":"El\u00e9fant E, Hanin C, Cohen D. Pregnant women, prescription, and fetal risk. Handb Clin Neurol. 2020;173:377\u201389.","journal-title":"Handb Clin Neurol."},{"key":"1077_CR2","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.53738\/REVMED.2018.14.614.1397","volume":"14","author":"S Wijayasinghe","year":"2018","unstructured":"Wijayasinghe S, Bentvelzen A, Guenot C, Murtezi J. Naus\u00e9es et vomissements chez la femme enceinte. Rev M\u00e9dicale Suisse. 2018;14:1397\u2013400.","journal-title":"Rev M\u00e9dicale Suisse."},{"issue":"309\u201334","key":"1077_CR3","first-page":"vii","volume":"40","author":"NM Lee","year":"2011","unstructured":"Lee NM, Saha S. Nausea and vomiting of pregnancy. Gastroenterol Clin North Am. 2011;40(309\u201334):vii.","journal-title":"Gastroenterol Clin North Am."},{"key":"1077_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41572-019-0110-3","volume":"5","author":"MS Fejzo","year":"2019","unstructured":"Fejzo MS, Trovik J, Grooten IJ, Sridharan K, Roseboom TJ, Vikanes \u00c5, et al. Nausea and vomiting of pregnancy and hyperemesis gravidarum. Nat Rev Dis Primer. 2019;5:62.","journal-title":"Nat Rev Dis Primer."},{"key":"1077_CR5","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00228-009-0647-2","volume":"65","author":"I Lacroix","year":"2009","unstructured":"Lacroix I, Hurault C, Sarramon MF, Guitard C, Berrebi A, Grau M, et al. Prescription of drugs during pregnancy: a study using EFEMERIS, the new French database. Eur J Clin Pharmacol. 2009;65:839\u201346.","journal-title":"Eur J Clin Pharmacol."},{"key":"1077_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2020.07.002","author":"M Araujo","year":"2020","unstructured":"Araujo M, Hurault-Delarue C, Sommet A, Damase-Michel C, Benevent J, Lacroix I. Drug prescriptions in French pregnant women between 2015 and 2016: a study in the EGB database. Therapie. 2020. https:\/\/doi.org\/10.1016\/j.therap.2020.07.002 (Epub ahead of print).","journal-title":"Therapie."},{"key":"1077_CR7","volume-title":"Catalog of teratogenic agents","author":"T Hara","year":"1992","unstructured":"Hara T, Nishikawa S, Miyazaki E, Ogura T. Toxicologic studies on KW-5338 reproductive studies: Yakuri to Chiryo. In: Shepard TH, editor. Catalog of teratogenic agents. 7th ed. Baltimore: JHU Press; 1992.","edition":"7"},{"key":"1077_CR8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3109\/01443615.2012.734871","volume":"33","author":"J-S Choi","year":"2013","unstructured":"Choi J-S, Han J-Y, Ahn H-K, Ryu H-M, Kim M-Y, Yang J-H, et al. Fetal and neonatal outcomes in women taking domperidone during pregnancy. J Obstet Gynaecol. 2013;33:160\u20132.","journal-title":"J Obstet Gynaecol."},{"key":"1077_CR9","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1093\/aje\/kwm324","volume":"167","author":"S Suissa","year":"2008","unstructured":"Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167:492\u20139.","journal-title":"Am J Epidemiol."},{"key":"1077_CR10","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2515\/therapie\/2014207","volume":"70","author":"J-L Faillie","year":"2015","unstructured":"Faillie J-L. Suissa S [Immortal time bias in pharmacoepidemiological studies: definition, solutions and examples]. Therapie. 2015;70:259\u201363.","journal-title":"Therapie"},{"key":"1077_CR11","unstructured":"Haute Autorit\u00e9 de Sant\u00e9. Sp\u00e9cialit\u00e9s \u00e0 base de domp\u00e9ridone, stimulant de la motricit\u00e9 intestinale. 2015 July: p. 1\u20132. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2016-03\/domperidone_reevaluation__synthese.pdf. Accessed 1 May 2021."},{"key":"1077_CR12","unstructured":"Lettre aux professionnels de sant\u00e9: m\u00e9dicaments \u00e0 base de domp\u00e9ridone et s\u00e9curit\u00e9 d\u2019emploi cardiovasculaire. https:\/\/www.ansm.sante.fr\/var\/ansm_site\/storage\/original\/application\/97997c1b053192166a1fdc206100e5b8.pdf. Accessed 14 Feb 2020."},{"key":"1077_CR13","unstructured":"M\u00e9dicaments contenant de la domp\u00e9ridone\u202f: Nouvelles recommandations visant \u00e0 minimiser les risques cardiaqueshttps:\/\/www.ansm.sante.fr\/var\/ansm_site\/storage\/original\/application\/d69ab2c62781a8ba78fa1a54e9357193.pdf. Accessed 14 Feb 2020."},{"key":"1077_CR14","doi-asserted-by":"publisher","first-page":"505","DOI":"10.2515\/therapie:2003082","volume":"58","author":"M-N Beyens","year":"2003","unstructured":"Beyens M-N, Guy C, Ratrema M, Ollagnier M. Prescription of drugs to pregnant women in France: the HIMAGE study. Therapie. 2003;58:505\u201311.","journal-title":"Therapie."},{"key":"1077_CR15","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1001\/jama.2013.278343","volume":"310","author":"B Pasternak","year":"2013","unstructured":"Pasternak B, Svanstr\u00f6m H, M\u00f8lgaard-Nielsen D, Melbye M, Hviid A. Metoclopramide in pregnancy and risk of major congenital malformations and fetal death. JAMA. 2013;310:1601\u201311.","journal-title":"JAMA"},{"key":"1077_CR16","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12958-018-0415-1","volume":"16","author":"PG Whittaker","year":"2018","unstructured":"Whittaker PG, Schreiber CA, Sammel MD. Gestational hormone trajectories and early pregnancy failure: a reassessment. Reprod Biol Endocrinol. 2018;16:95.","journal-title":"Reprod Biol Endocrinol."},{"key":"1077_CR17","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1097\/OGX.0000000000000654","volume":"74","author":"I Tsakiridis","year":"2019","unstructured":"Tsakiridis I, Mamopoulos A, Athanasiadis A, Dagklis T. The management of nausea and vomiting of pregnancy: synthesis of national guidelines. Obstet Gynecol Surv. 2019;74:161\u20139.","journal-title":"Obstet Gynecol Surv."},{"key":"1077_CR18","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/bdra.22865","volume":"94","author":"M Anderka","year":"2012","unstructured":"Anderka M, Mitchell AA, Louik C, Werler MM, Hern\u00e1ndez-Diaz S, Rasmussen SA, et al. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birt Defects Res A Clin Mol Teratol. 2012;94:22\u201330.","journal-title":"Birt Defects Res A Clin Mol Teratol."},{"key":"1077_CR19","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.reprotox.2014.10.017","volume":"50","author":"B Danielsson","year":"2014","unstructured":"Danielsson B, Wikner BN, K\u00e4ll\u00e9n B. Use of ondansetron during pregnancy and congenital malformations in the infant. Reprod Toxicol. 2014;50:134\u20137.","journal-title":"Reprod Toxicol."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01077-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-021-01077-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-021-01077-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,26]],"date-time":"2022-12-26T21:38:45Z","timestamp":1672090725000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-021-01077-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,10]]},"references-count":19,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["1077"],"URL":"https:\/\/doi.org\/10.1007\/s40264-021-01077-9","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,10]]},"assertion":[{"value":"23 April 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study is part of the REproduction Gestation And Reproduction (REGARDS) research programme funded by the Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des produits de sant\u00e9 (ANSM) [French National Agency for the Safety of Medicines and Health Products]. This programme aims to improve drug monitoring in pregnant women, in France. Allocation of funding did not impact the study design and conduct, data collection, management, analysis and interpretation or the preparation, review and approval of the manuscript. This publication represents the views of the authors and does not necessarily represent the opinion of the French Medicines Agency.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"M\u00e9lanie Araujo, Cl\u00e9mentine Vabre, Justine Benevent, Agn\u00e8s Sommet, Christine Damase-Michel, Caroline Hurault-Delarue and Isabelle Lacroix have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest\/Competing interests"}},{"value":"The EFEMERIS cohort was approved by the French Data Protection Agency on 7 April, 2005 (authorisation number 05-1140). This study was performed on anonymised patient data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The women included in EFEMERIS were informed of their inclusion and of the potential use of their anonymised data for research purposes. They can oppose the use of their data at any time.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The women included in EFEMERIS know that their gathered and anonymised data can be used for medical research purposes and can thus be published.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Because of the nature of this research, participants of this study did not agree for their data to be shared publicly, thus supporting data are not available.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Study design: MA, CH-D, IL. Data acquisition, analysis or interpretation: MA, CV, CH-D, IL. Drafting of the manuscript: MA, CH-D, IL. Critical review of the manuscript for significant intellectual content: MA, CV, CH-D, AS, CD-M, JB, IL. All authors had full access to all study data and are responsible for the integrity of the data and the accuracy of the data analysis. All authors have read and approved the final version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 contributions"}}]}}